Table 2. Univariate analysis for the association between clinical factors and survival outcomes.

Characteristics	Progression free survival		Overall survival
	HR (95% CI)	P value	HR (95% CI)	P value
Serum B2M ≥ 2.5 mg/L	3.59 (2.82–4.56)	< 0.001	4.16 (3.16–5.48)	< 0.001
Age > 60 years	2.72 (2.13–3.46)	< 0.001	3.01 (2.28–3.95)	< 0.001
Female	0.89 (0.70–1.13)	0.327	0.99 (0.76–1.30)	0.962
ECOG PS, 2–4	3.99 (2.95–5.41)	< 0.001	4.17 (2.99–5.82)	< 0.001
Serum LDH > UNL	3.69 (2.83–4.80)	< 0.001	3.78 (2.80–5.10)	< 0.001
Ann Arbor stage, III–IV	3.20 (2.44–4.20)	< 0.001	3.49 (2.57–4.76)	< 0.001
Extranodal sites ≥ 2	2.72 (2.15–3.46)	< 0.001	2.93 (2.24–3.82)	< 0.001
B symptoms	2.37 (1.85–3.03)	< 0.001	2.39 (1.82–3.15)	< 0.001
Non-GCB type by the Hans algorithma	1.40 (1.04–1.88)	0.026	1.50 (1.07–2.10)	0.019
Bone marrow involvement	1.91 (1.44–2.54)	< 0.001	1.82 (1.32–2.51)	< 0.001
Bulky disease > 10 cm	1.61 (1.10–2.35)	0.014	1.51 (0.98–2.33)	0.061
Estimated GFR < 60	2.26 (1.59-3.23)	< 0.001	2.52 (1.71-3.70)	< 0.001
IPI
Low (0–1)	1		1
Low-intermediate (2)	1.90 (1.29–2.79)	0.001	1.81 (1.14–2.87)	0.012
High-intermediate (3)	3.13 (2.22–4.42)	< 0.001	3.81 (2.59–5.61)	< 0.001
High (4–5)	7.29 (5.35–9.94)	< 0.001	7.88 (5.53–11.22)	< 0.001
Revised IPI
Very good (0)	1		1
Good (1–2)	3.44 (2.07–5.70)	< 0.001	2.91 (1.65–2.52)	< 0.001
Poor (3–5)	9.64 (5.93–15.69)	< 0.001	10.05(5.80–17.41)	< 0.001
NCCN-IPI
Low (0–1)	1		1
Low-intermediate (2–3)	2.48 (1.43–4.29)	0.001	2.98 (1.49–5.99)	0.002
High-intermediate (4–5)	7.12 (4.16–12.17)	< 0.001	9.10 (4.60–17.99)	< 0.001
High (≥ 6)	17.17 (9.60–30.72)	< 0.001	24.47 (11.90–50.32)	< 0.001

Abbreviations: B2M, beta-2 microglobulin; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center-like B cell-like; HR, hazard ratio; IPI, International Prognostic index LDH, lactate dehydrogenase; NCCN, National Comprehensive Cancer Network; PS, performance score; UNL, upper normal limit to.

^aData for the Hans algorithm were available in 693 patients.